Global Opioids Drug
Global Opioids Drug

Opioids Drug Comprehensive Study by Type (Morphine, Codeine, Fentanyl, Meperidine, Methadone, Others), Application (Pain Management, Cough Supression, Diarrhea Suppresion, Others), Receptor Binding (Strong Agonist, Mild to Moderate Agonist) Players and Region - Global Market Outlook to 2024

Opioids Drug Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024 | CAGR: 2.1%  

May 2019 Edition 204 Pages 213 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Opioids Drug Market Overview:
The opioids drugs is a type of narcotic pain medication that applicable for treatment of severe pain. It is used as an anesthesia, cough suppressant, diarrhea suppressant and to reduce surgical pain. As the numbers of critically ill patients are increasing, demand for orthopedic diseases is also on the rise, leading to growing demand of opioids drugs. There has been significant rise in number of people additives towards opioid overdoses in the U.S. daily with figure stood up to 115 death toll in daily. It also witnessed that 21 to 29 percent of patients who are prescribed opioids for chronic pain misuse them, with 8 to 12 percent developing an opioid use disorder. The major companies are organized awareness programs in Asia-Pacific and Middle East region to prescribe painkillers to help patients overcome opiophobia. According to AMA, the Global Opioids Drug market is expected to see growth rate of 2.1% and may see market size of USD24321.0 Million by 2024.

Market Drivers
  • Increasing Surgical Procedures and Road Accidents.
  • Growing Occurrence of Chronic Pain.

Market Trend
  • Rising Demand for opioids drugs in healthcare industries.
  • Value Oriented Consumers

Restraints
  • Misuse of Opioids and Consequential Stringent Regulations Hampers the Growth Of Market.
  • Rehabilitation Centers Used Methadone and Buprenorphine that Gradually Decreased the Used of Addictive Opioids.

Opportunities
  • Rising Demands of Opioids Drugs in Cough Suppressant and Diarrhea Suppressant.
  • Growing Palliative Care Facilities Boost the Opioids Drugs Market.

Challenges
  • Legalization of Cannabis as Alternatives of Cannabis may challenge the Market of Opioids Drugs.


Competitive Landscape:

Some of the key players profiled in the report are Purdue Pharma L.P (United States), Allergan (Ireland), West-Ward Pharmaceuticals Corporation (United States), Janssen Pharmaceuticals, Inc. (Belgium), Pfizer, Inc. (United States), Egalet Corporation (United States), Sun Pharmaceutical Industries Limited (India), Acura Pharmaceuticals Inc. (United States), Cipher Pharmaceutical Inc. (Canada) and Daiichi Sankyo Inc. (Canada). Additionally, following companies can also be profiled that are part of our coverage like Johnson & Johnson (United States), Lupin Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Actavis Plc (United States), and Egalet (United States). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Opioids Drug market by 2024. Considering Market by Receptor Binding, the sub-segment i.e. Strong Agonist will boost the Opioids Drug market.

Market Highlights:

In April 2019, U.S. Food and Drug Administration launched a public education campaign which is beneficial in providing safe removal of unused opioid pain medicines from homes. It also introduced a “Remove and Risk” Campaign that telecast in television, radio and print public announcements that can used by different organizations, individuals and healthcare providers.

“According to Department of Health and Human Services, Its launched some strategy to combat against opioids addiction, the strategy consist of prevention, treatment and recovery services, data on the epidemic, pain management, targeting of overdose-reversing drugs and research on pain and addiction.”

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Opioids Drug market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Opioids Drug market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Opioids Drugs Manufacturers, Opioids Drugs Traders, End-Use Market Participants of Different Segments of Opioids Drugs, Government and Research Organizations, R&D Institutions and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Morphine
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Others
By Application
  • Pain Management
  • Cough Supression
  • Diarrhea Suppresion
  • Others
By Receptor Binding
  • Strong Agonist
  • Mild to Moderate Agonist

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Surgical Procedures and Road Accidents.
      • 3.2.2. Growing Occurrence of Chronic Pain.
    • 3.3. Market Challenges
      • 3.3.1. Legalization of Cannabis as Alternatives of Cannabis may challenge the Market of Opioids Drugs.
    • 3.4. Market Trends
      • 3.4.1. Rising Demand for opioids drugs in healthcare industries.
      • 3.4.2. Value Oriented Consumers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Opioids Drug, by Type, Application, Receptor Binding and Region (value and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Opioids Drug (Value)
      • 5.2.1. Global Opioids Drug by: Type (Value)
        • 5.2.1.1. Morphine
        • 5.2.1.2. Codeine
        • 5.2.1.3. Fentanyl
        • 5.2.1.4. Meperidine
        • 5.2.1.5. Methadone
        • 5.2.1.6. Others
      • 5.2.2. Global Opioids Drug by: Application (Value)
        • 5.2.2.1. Pain Management
        • 5.2.2.2. Cough Supression
        • 5.2.2.3. Diarrhea Suppresion
        • 5.2.2.4. Others
      • 5.2.3. Global Opioids Drug by: Receptor Binding (Value)
        • 5.2.3.1. Strong Agonist
        • 5.2.3.2. Mild to Moderate Agonist
      • 5.2.4. Global Opioids Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Opioids Drug (Price)
      • 5.3.1. Global Opioids Drug by: Type (Price)
  • 6. Opioids Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Purdue Pharma L.P (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Allergan (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. West-Ward Pharmaceuticals Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Janssen Pharmaceuticals, Inc. (Belgium)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Egalet Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sun Pharmaceutical Industries Limited (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Acura Pharmaceuticals Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cipher Pharmaceutical Inc. (Canada)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Daiichi Sankyo Inc. (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Opioids Drug Sale, by Type, Application, Receptor Binding and Region (value and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Opioids Drug (Value)
      • 7.2.1. Global Opioids Drug by: Type (Value)
        • 7.2.1.1. Morphine
        • 7.2.1.2. Codeine
        • 7.2.1.3. Fentanyl
        • 7.2.1.4. Meperidine
        • 7.2.1.5. Methadone
        • 7.2.1.6. Others
      • 7.2.2. Global Opioids Drug by: Application (Value)
        • 7.2.2.1. Pain Management
        • 7.2.2.2. Cough Supression
        • 7.2.2.3. Diarrhea Suppresion
        • 7.2.2.4. Others
      • 7.2.3. Global Opioids Drug by: Receptor Binding (Value)
        • 7.2.3.1. Strong Agonist
        • 7.2.3.2. Mild to Moderate Agonist
      • 7.2.4. Global Opioids Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Opioids Drug (Price)
      • 7.3.1. Global Opioids Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Opioids Drug: by Type(USD Million)
  • Table 2. Opioids Drug Morphine , by Region USD Million (2013-2018)
  • Table 3. Opioids Drug Codeine , by Region USD Million (2013-2018)
  • Table 4. Opioids Drug Fentanyl , by Region USD Million (2013-2018)
  • Table 5. Opioids Drug Meperidine , by Region USD Million (2013-2018)
  • Table 6. Opioids Drug Methadone , by Region USD Million (2013-2018)
  • Table 7. Opioids Drug Others , by Region USD Million (2013-2018)
  • Table 8. Opioids Drug: by Application(USD Million)
  • Table 9. Opioids Drug Pain Management , by Region USD Million (2013-2018)
  • Table 10. Opioids Drug Cough Supression , by Region USD Million (2013-2018)
  • Table 11. Opioids Drug Diarrhea Suppresion , by Region USD Million (2013-2018)
  • Table 12. Opioids Drug Others , by Region USD Million (2013-2018)
  • Table 13. Opioids Drug: by Receptor Binding(USD Million)
  • Table 14. Opioids Drug Strong Agonist , by Region USD Million (2013-2018)
  • Table 15. Opioids Drug Mild to Moderate Agonist , by Region USD Million (2013-2018)
  • Table 16. South America Opioids Drug, by Country USD Million (2013-2018)
  • Table 17. South America Opioids Drug, by Type USD Million (2013-2018)
  • Table 18. South America Opioids Drug, by Application USD Million (2013-2018)
  • Table 19. South America Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 20. Brazil Opioids Drug, by Type USD Million (2013-2018)
  • Table 21. Brazil Opioids Drug, by Application USD Million (2013-2018)
  • Table 22. Brazil Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 23. Argentina Opioids Drug, by Type USD Million (2013-2018)
  • Table 24. Argentina Opioids Drug, by Application USD Million (2013-2018)
  • Table 25. Argentina Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 26. Rest of South America Opioids Drug, by Type USD Million (2013-2018)
  • Table 27. Rest of South America Opioids Drug, by Application USD Million (2013-2018)
  • Table 28. Rest of South America Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 29. Asia Pacific Opioids Drug, by Country USD Million (2013-2018)
  • Table 30. Asia Pacific Opioids Drug, by Type USD Million (2013-2018)
  • Table 31. Asia Pacific Opioids Drug, by Application USD Million (2013-2018)
  • Table 32. Asia Pacific Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 33. China Opioids Drug, by Type USD Million (2013-2018)
  • Table 34. China Opioids Drug, by Application USD Million (2013-2018)
  • Table 35. China Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 36. Japan Opioids Drug, by Type USD Million (2013-2018)
  • Table 37. Japan Opioids Drug, by Application USD Million (2013-2018)
  • Table 38. Japan Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 39. India Opioids Drug, by Type USD Million (2013-2018)
  • Table 40. India Opioids Drug, by Application USD Million (2013-2018)
  • Table 41. India Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 42. South Korea Opioids Drug, by Type USD Million (2013-2018)
  • Table 43. South Korea Opioids Drug, by Application USD Million (2013-2018)
  • Table 44. South Korea Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 45. Taiwan Opioids Drug, by Type USD Million (2013-2018)
  • Table 46. Taiwan Opioids Drug, by Application USD Million (2013-2018)
  • Table 47. Taiwan Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 48. Australia Opioids Drug, by Type USD Million (2013-2018)
  • Table 49. Australia Opioids Drug, by Application USD Million (2013-2018)
  • Table 50. Australia Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 51. Rest of Asia-Pacific Opioids Drug, by Type USD Million (2013-2018)
  • Table 52. Rest of Asia-Pacific Opioids Drug, by Application USD Million (2013-2018)
  • Table 53. Rest of Asia-Pacific Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 54. Europe Opioids Drug, by Country USD Million (2013-2018)
  • Table 55. Europe Opioids Drug, by Type USD Million (2013-2018)
  • Table 56. Europe Opioids Drug, by Application USD Million (2013-2018)
  • Table 57. Europe Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 58. Germany Opioids Drug, by Type USD Million (2013-2018)
  • Table 59. Germany Opioids Drug, by Application USD Million (2013-2018)
  • Table 60. Germany Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 61. France Opioids Drug, by Type USD Million (2013-2018)
  • Table 62. France Opioids Drug, by Application USD Million (2013-2018)
  • Table 63. France Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 64. Italy Opioids Drug, by Type USD Million (2013-2018)
  • Table 65. Italy Opioids Drug, by Application USD Million (2013-2018)
  • Table 66. Italy Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 67. United Kingdom Opioids Drug, by Type USD Million (2013-2018)
  • Table 68. United Kingdom Opioids Drug, by Application USD Million (2013-2018)
  • Table 69. United Kingdom Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 70. Netherlands Opioids Drug, by Type USD Million (2013-2018)
  • Table 71. Netherlands Opioids Drug, by Application USD Million (2013-2018)
  • Table 72. Netherlands Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 73. Rest of Europe Opioids Drug, by Type USD Million (2013-2018)
  • Table 74. Rest of Europe Opioids Drug, by Application USD Million (2013-2018)
  • Table 75. Rest of Europe Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 76. MEA Opioids Drug, by Country USD Million (2013-2018)
  • Table 77. MEA Opioids Drug, by Type USD Million (2013-2018)
  • Table 78. MEA Opioids Drug, by Application USD Million (2013-2018)
  • Table 79. MEA Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 80. Middle East Opioids Drug, by Type USD Million (2013-2018)
  • Table 81. Middle East Opioids Drug, by Application USD Million (2013-2018)
  • Table 82. Middle East Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 83. Africa Opioids Drug, by Type USD Million (2013-2018)
  • Table 84. Africa Opioids Drug, by Application USD Million (2013-2018)
  • Table 85. Africa Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 86. North America Opioids Drug, by Country USD Million (2013-2018)
  • Table 87. North America Opioids Drug, by Type USD Million (2013-2018)
  • Table 88. North America Opioids Drug, by Application USD Million (2013-2018)
  • Table 89. North America Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 90. United States Opioids Drug, by Type USD Million (2013-2018)
  • Table 91. United States Opioids Drug, by Application USD Million (2013-2018)
  • Table 92. United States Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 93. Canada Opioids Drug, by Type USD Million (2013-2018)
  • Table 94. Canada Opioids Drug, by Application USD Million (2013-2018)
  • Table 95. Canada Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 96. Mexico Opioids Drug, by Type USD Million (2013-2018)
  • Table 97. Mexico Opioids Drug, by Application USD Million (2013-2018)
  • Table 98. Mexico Opioids Drug, by Receptor Binding USD Million (2013-2018)
  • Table 99. Opioids Drug: by Type(USD/Units)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Opioids Drug: by Type(USD Million)
  • Table 111. Opioids Drug Morphine , by Region USD Million (2019-2024)
  • Table 112. Opioids Drug Codeine , by Region USD Million (2019-2024)
  • Table 113. Opioids Drug Fentanyl , by Region USD Million (2019-2024)
  • Table 114. Opioids Drug Meperidine , by Region USD Million (2019-2024)
  • Table 115. Opioids Drug Methadone , by Region USD Million (2019-2024)
  • Table 116. Opioids Drug Others , by Region USD Million (2019-2024)
  • Table 117. Opioids Drug: by Application(USD Million)
  • Table 118. Opioids Drug Pain Management , by Region USD Million (2019-2024)
  • Table 119. Opioids Drug Cough Supression , by Region USD Million (2019-2024)
  • Table 120. Opioids Drug Diarrhea Suppresion , by Region USD Million (2019-2024)
  • Table 121. Opioids Drug Others , by Region USD Million (2019-2024)
  • Table 122. Opioids Drug: by Receptor Binding(USD Million)
  • Table 123. Opioids Drug Strong Agonist , by Region USD Million (2019-2024)
  • Table 124. Opioids Drug Mild to Moderate Agonist , by Region USD Million (2019-2024)
  • Table 125. South America Opioids Drug, by Country USD Million (2019-2024)
  • Table 126. South America Opioids Drug, by Type USD Million (2019-2024)
  • Table 127. South America Opioids Drug, by Application USD Million (2019-2024)
  • Table 128. South America Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 129. Brazil Opioids Drug, by Type USD Million (2019-2024)
  • Table 130. Brazil Opioids Drug, by Application USD Million (2019-2024)
  • Table 131. Brazil Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 132. Argentina Opioids Drug, by Type USD Million (2019-2024)
  • Table 133. Argentina Opioids Drug, by Application USD Million (2019-2024)
  • Table 134. Argentina Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 135. Rest of South America Opioids Drug, by Type USD Million (2019-2024)
  • Table 136. Rest of South America Opioids Drug, by Application USD Million (2019-2024)
  • Table 137. Rest of South America Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 138. Asia Pacific Opioids Drug, by Country USD Million (2019-2024)
  • Table 139. Asia Pacific Opioids Drug, by Type USD Million (2019-2024)
  • Table 140. Asia Pacific Opioids Drug, by Application USD Million (2019-2024)
  • Table 141. Asia Pacific Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 142. China Opioids Drug, by Type USD Million (2019-2024)
  • Table 143. China Opioids Drug, by Application USD Million (2019-2024)
  • Table 144. China Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 145. Japan Opioids Drug, by Type USD Million (2019-2024)
  • Table 146. Japan Opioids Drug, by Application USD Million (2019-2024)
  • Table 147. Japan Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 148. India Opioids Drug, by Type USD Million (2019-2024)
  • Table 149. India Opioids Drug, by Application USD Million (2019-2024)
  • Table 150. India Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 151. South Korea Opioids Drug, by Type USD Million (2019-2024)
  • Table 152. South Korea Opioids Drug, by Application USD Million (2019-2024)
  • Table 153. South Korea Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 154. Taiwan Opioids Drug, by Type USD Million (2019-2024)
  • Table 155. Taiwan Opioids Drug, by Application USD Million (2019-2024)
  • Table 156. Taiwan Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 157. Australia Opioids Drug, by Type USD Million (2019-2024)
  • Table 158. Australia Opioids Drug, by Application USD Million (2019-2024)
  • Table 159. Australia Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 160. Rest of Asia-Pacific Opioids Drug, by Type USD Million (2019-2024)
  • Table 161. Rest of Asia-Pacific Opioids Drug, by Application USD Million (2019-2024)
  • Table 162. Rest of Asia-Pacific Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 163. Europe Opioids Drug, by Country USD Million (2019-2024)
  • Table 164. Europe Opioids Drug, by Type USD Million (2019-2024)
  • Table 165. Europe Opioids Drug, by Application USD Million (2019-2024)
  • Table 166. Europe Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 167. Germany Opioids Drug, by Type USD Million (2019-2024)
  • Table 168. Germany Opioids Drug, by Application USD Million (2019-2024)
  • Table 169. Germany Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 170. France Opioids Drug, by Type USD Million (2019-2024)
  • Table 171. France Opioids Drug, by Application USD Million (2019-2024)
  • Table 172. France Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 173. Italy Opioids Drug, by Type USD Million (2019-2024)
  • Table 174. Italy Opioids Drug, by Application USD Million (2019-2024)
  • Table 175. Italy Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 176. United Kingdom Opioids Drug, by Type USD Million (2019-2024)
  • Table 177. United Kingdom Opioids Drug, by Application USD Million (2019-2024)
  • Table 178. United Kingdom Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 179. Netherlands Opioids Drug, by Type USD Million (2019-2024)
  • Table 180. Netherlands Opioids Drug, by Application USD Million (2019-2024)
  • Table 181. Netherlands Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 182. Rest of Europe Opioids Drug, by Type USD Million (2019-2024)
  • Table 183. Rest of Europe Opioids Drug, by Application USD Million (2019-2024)
  • Table 184. Rest of Europe Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 185. MEA Opioids Drug, by Country USD Million (2019-2024)
  • Table 186. MEA Opioids Drug, by Type USD Million (2019-2024)
  • Table 187. MEA Opioids Drug, by Application USD Million (2019-2024)
  • Table 188. MEA Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 189. Middle East Opioids Drug, by Type USD Million (2019-2024)
  • Table 190. Middle East Opioids Drug, by Application USD Million (2019-2024)
  • Table 191. Middle East Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 192. Africa Opioids Drug, by Type USD Million (2019-2024)
  • Table 193. Africa Opioids Drug, by Application USD Million (2019-2024)
  • Table 194. Africa Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 195. North America Opioids Drug, by Country USD Million (2019-2024)
  • Table 196. North America Opioids Drug, by Type USD Million (2019-2024)
  • Table 197. North America Opioids Drug, by Application USD Million (2019-2024)
  • Table 198. North America Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 199. United States Opioids Drug, by Type USD Million (2019-2024)
  • Table 200. United States Opioids Drug, by Application USD Million (2019-2024)
  • Table 201. United States Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 202. Canada Opioids Drug, by Type USD Million (2019-2024)
  • Table 203. Canada Opioids Drug, by Application USD Million (2019-2024)
  • Table 204. Canada Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 205. Mexico Opioids Drug, by Type USD Million (2019-2024)
  • Table 206. Mexico Opioids Drug, by Application USD Million (2019-2024)
  • Table 207. Mexico Opioids Drug, by Receptor Binding USD Million (2019-2024)
  • Table 208. Opioids Drug: by Type(USD/Units)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Opioids Drug: by Type USD Million (2013-2018)
  • Figure 5. Global Opioids Drug: by Application USD Million (2013-2018)
  • Figure 6. Global Opioids Drug: by Receptor Binding USD Million (2013-2018)
  • Figure 7. South America Opioids Drug Share (%), by Country
  • Figure 8. Asia Pacific Opioids Drug Share (%), by Country
  • Figure 9. Europe Opioids Drug Share (%), by Country
  • Figure 10. MEA Opioids Drug Share (%), by Country
  • Figure 11. North America Opioids Drug Share (%), by Country
  • Figure 12. Global Opioids Drug: by Type USD/Units (2013-2018)
  • Figure 13. Global Opioids Drug share by Players 2018 (%)
  • Figure 14. Global Opioids Drug share by Players (Top 3) 2018(%)
  • Figure 15. Global Opioids Drug share by Players (Top 5) 2018(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Purdue Pharma L.P (United States) Revenue, Net Income and Gross profit
  • Figure 18. Purdue Pharma L.P (United States) Revenue: by Geography 2018
  • Figure 19. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 20. Allergan (Ireland) Revenue: by Geography 2018
  • Figure 21. West-Ward Pharmaceuticals Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 22. West-Ward Pharmaceuticals Corporation (United States) Revenue: by Geography 2018
  • Figure 23. Janssen Pharmaceuticals, Inc. (Belgium) Revenue, Net Income and Gross profit
  • Figure 24. Janssen Pharmaceuticals, Inc. (Belgium) Revenue: by Geography 2018
  • Figure 25. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer, Inc. (United States) Revenue: by Geography 2018
  • Figure 27. Egalet Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. Egalet Corporation (United States) Revenue: by Geography 2018
  • Figure 29. Sun Pharmaceutical Industries Limited (India) Revenue, Net Income and Gross profit
  • Figure 30. Sun Pharmaceutical Industries Limited (India) Revenue: by Geography 2018
  • Figure 31. Acura Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Acura Pharmaceuticals Inc. (United States) Revenue: by Geography 2018
  • Figure 33. Cipher Pharmaceutical Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 34. Cipher Pharmaceutical Inc. (Canada) Revenue: by Geography 2018
  • Figure 35. Daiichi Sankyo Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 36. Daiichi Sankyo Inc. (Canada) Revenue: by Geography 2018
  • Figure 37. Global Opioids Drug: by Type USD Million (2019-2024)
  • Figure 38. Global Opioids Drug: by Application USD Million (2019-2024)
  • Figure 39. Global Opioids Drug: by Receptor Binding USD Million (2019-2024)
  • Figure 40. South America Opioids Drug Share (%), by Country
  • Figure 41. Asia Pacific Opioids Drug Share (%), by Country
  • Figure 42. Europe Opioids Drug Share (%), by Country
  • Figure 43. MEA Opioids Drug Share (%), by Country
  • Figure 44. North America Opioids Drug Share (%), by Country
  • Figure 45. Global Opioids Drug: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Purdue Pharma L.P (United States)
  • Allergan (Ireland)
  • West-Ward Pharmaceuticals Corporation (United States)
  • Janssen Pharmaceuticals, Inc. (Belgium)
  • Pfizer, Inc. (United States)
  • Egalet Corporation (United States)
  • Sun Pharmaceutical Industries Limited (India)
  • Acura Pharmaceuticals Inc. (United States)
  • Cipher Pharmaceutical Inc. (Canada)
  • Daiichi Sankyo Inc. (Canada)
Additional players considered in the study are as follows:
Johnson & Johnson (United States) , Lupin Ltd. (India) , Teva Pharmaceutical Industries Ltd. (Israel) , Actavis Plc (United States), , Egalet (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation